Status:
COMPLETED
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30-65 years
Phase:
PHASE3
Brief Summary
Please note this study is not being conducted in the United States. The purpose of this study is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal glucose levels b...
Eligibility Criteria
Inclusion
- Must be able to complete a 1-week wash-out of current anti-diabetic medications
- Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose
- Blood glucose criteria must be met
- BMI \<40
Exclusion
- History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- Need for insulin within 3 months or patients on thiazolidinediones
- Significant concommitant disease or complications of diabetes
- Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons
- Abnormal liver function tests as defined by the protocol
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00380380
Start Date
January 1 2006
End Date
November 1 2006
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Munich, 81377, Germany
Munich, Germany